Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment of
hematologic malignancies in patients with relapsed or refractory disease without other …

Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …

Abstract Chimeric Antigen Receptor (CAR) T cell immunotherapy is revolutionizing treatment
for patients suffering from B‐cell lymphoma (BL). However, the current method of CAR T cell …

The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous
revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products …

Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved striking success in some …

Cellular immunotherapy has revolutionized the oncology field, yielding improved results
against hematological and solid malignancies. NK cells have become an attractive …

T cell engineering, particularly via chimeric antigen receptor (CAR) modifications for
enhancing tumor specificity, has shown efficacy in treating hematologic malignancies. The …

Chimeric antigen receptor (CAR)-T cell therapies have revolutionized cancer treatment,
particularly in hematological malignancies. However, their application to solid tumors is …

Cancer research has played a pivotal role in improving patient outcomes. However, despite
the significant investment in fundamental cancer research over the past few decades, the …

Chimeric antigen receptor (CAR)-T cell therapy is a promising new treatment for cancer that
involves genetically modifying a patient's T-cells to recognize and attack cancer cells. This …